Vascular Solutions lands within analysts’ expectations and raises guidance estimates, but sees a slight dip in shares.
Vascular Solutions’ (NSDQ:VASC) Q2 earnings landed exactly within analyst expectations, ending the company’s long streak of beating the Street.
Despite driving profits up almost 20% and boosting guidance estimates to reflect healthy revenue, Wall Street responded by sending share prices down 0.7% by the end of the day.